Effectiveness, saf ety, and cost of combination advanced therapies in inflammatory bowel disease

被引：3

作者：

Mcshane, Cathy ^{[1
,10
,11
]}

Varley, Rachel ^{[2
]}

Fennessy, Anne ^{[3
]}

Byron, Clodagh ^{[4
]}

Campion, John Richard ^{[5
]}

Hazel, Karl ^{[6
]}

Costigan, Conor ^{[7
,11
]}

Ring, Eabha ^{[8
]}

Marrinan, Alan ^{[9
]}

Judge, Ciaran ^{[2
]}

Sugrue, Kathleen ^{[2
]}

Cullen, Garret ^{[3
,13
]}

Dunne, Cara ^{[1
,11
,13
]}

Hartery, Karen ^{[1
,11
,13
]}

Iacucci, Marietta ^{[2
,12
,13
]}

Kelly, Orlaith ^{[8
,13
]}

Leyden, Jan ^{[9
,13
]}

McKiernan, Susan ^{[1
,11
]}

O'Toole, Aoibhlinn ^{[6
,13
]}

Sheridan, Juliette ^{[3
,13
]}

Slattery, Eoin ^{[5
]}

Boland, Karen ^{[6
]}

McNamara, Deirdre ^{[7
,11
]}

Egan, Laurence ^{[5
]}

Ghosh, Subrata ^{[4
,12
]}

Doherty, Glen ^{[3
]}

McCarthy, Jane ^{[2
]}

Kevans, David ^{[1
,10
,11
]}

机构：

[1] St James Hosp, Dept Gastroenterol, Dublin, Ireland

[2] Mercy Univ Hosp, Cork, Ireland

[3] St Vincents Univ Hosp, Ctr Colorectal Dis, Dublin, Ireland

[4] Cork Univ Hosp, Cork, Ireland

[5] Galway Univ Hosp, Galway, Ireland

[6] Beaumont Hosp, Dublin, Ireland

[7] Tallaght Univ Hosp, Dublin, Dublin, Ireland

[8] Connolly Hosp Blanchardstown, Dublin, Ireland

[9] Mater Misericordiae Univ Hosp, Dublin, Ireland

[10] St James Hosp, Wellcome HRB Clin Res Facil, Jamess St, Dublin, Ireland

[11] Trinity Coll Dublin, Trinity Acad Gastroenterol Grp, Dublin, Ireland

[12] Univ Coll Cork, Coll Med & Hlth, Cork, Ireland

[13] Initiat IBD Res Network, Dublin, Ireland

来源：

DIGESTIVE AND LIVER DISEASE | 2025年 / 57卷 / 01期

关键词：

Clinical trials; Combination advanced therapies; Inflammatory bowel disease; Biologic therapy; Small molecule therapy; MAINTENANCE THERAPY; INFLIXIMAB; AZATHIOPRINE; USTEKINUMAB; INDUCTION; REMISSION; EFFICACY;

D O I：

10.1016/j.dld.2024.08.055

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

Background: A significant proportion of inflammatory bowel disease (IBD) patients fail to respond to advanced therapies. Combining advanced therapies may improve treatment outcome. This study aimed to assess the effectiveness, adverse events, and costs associated with combining advanced therapies in IBD patients. Methods: Combination advanced therapy was defined as the concurrent use of two biological agents or one biological agent with a small molecule therapy. Clinical data, including disease characteristics, treatment regimens, and adverse events, were collected from electronic patient records. Clinical response rates, biochemical markers, and treatment costs were evaluated. Results: The study included 109 IBD patients receiving combination advanced therapies from 9 academic centers in Ireland. Corticosteroid-free clinical response rates at 12 weeks and 52 weeks were 39 % and 38 %, respectively. Adverse events occurred in 26 % of therapeutic trials, with disease-related events being the most common. Notably, there were 3 cases of non-melanomatous skin cancer and 10 infectious complications. The annual cost of maintenance therapy for combination advanced therapies ranged from <euro>17,560 to <euro>30,724 per patient. Conclusion: Combination advanced therapies demonstrated effectiveness and acceptable safety profiles in a cohort of treatment-refractory IBD patients. Further large, prospective trials are required to definitively evaluate the role of combination advanced therapies in IBD. (c) 2024 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.

引用

页码：274 / 281

页数：8

共 32 条

[1] Dual Biologic or Small Molecule Therapy for Treatment of Inflammatory Bowel Disease: A Systematic Review and Meta-analysis [J].